Page 406 - Williams Hematology ( PDFDrive )

380 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 381

376. Kanakry CG, O’Donnell PV, Furlong T, et al: Multi-institutional study of post-trans- 405. Sullivan KM, Witherspoon RP, Storb R, et al: Prednisone and azathioprine compared
plantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis with prednisone and placebo for treatment of chronic graft-v-host disease: Prognos-
after allogeneic bone marrow transplantation using myeloablative busulfan and fludar- tic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
abine conditioning. J Clin Oncol 32:3497–3505, 2014. Blood 72:546–554, 1988.
377. Anderson BE, Taylor PA, McNiff JM, et al: Effects of donor T-cell trafficking and prim- 406. Koc S, Leisenring W, Flowers ME, et al: Thalidomide for treatment of patients with
ing site on graft-versus-host disease induction by naive and memory phenotype CD4 T chronic graft-versus-host disease. Blood 96:3995–3996, 2000.
cells. Blood 111:5242–5251, 2008. 407. Arora M, Wagner JE, Davies SM, et al: Randomized clinical trial of thalidomide,
378. Chen BJ, Cui X, Sempowski GD, et al: Transfer of allogeneic CD62L– memory T cells cyclosporine, and prednisone versus cyclosporine and prednisone as initial ther-
without graft-versus-host disease. Blood 103:1534–1541, 2004. apy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 7:265–273,
379. Bleakley M, Heimfeld S, Jones LA, et al: Engineering human peripheral blood stem cell 2001.
grafts that are depleted of naive T cells and retain functional pathogen-specific memory 408. Koc S, Leisenring W, Flowers ME, et al: Therapy for chronic graft-versus-host disease:
T cells. Biol Blood Marrow Transplant 20:705–716, 2014. A randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
380. Brunstein CG, Miller JS, Cao Q, et al: Infusion of ex vivo expanded T regulatory cells Blood 100:48–51, 2002.
in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. 409. Martin PJ, Storer BE, Rowley SD, et al: Evaluation of mycophenolate mofetil for initial
Blood 117:1061–1070, 2011. treatment of chronic graft-versus-host disease. Blood 113:5074–5082, 2009.
381. Reshef R, Luger SM, Hexner EO, et al: Blockade of lymphocyte chemotaxis in visceral 410. Gilman AL, Schultz KR, Goldman FD, et al: Randomized trial of hydroxychloroquine
graft-versus-host disease. N Engl J Med 367:135–145, 2012. for newly diagnosed chronic graft-versus-host disease in children: A Children’s Oncol-
382. Bacigalupo A: Management of acute graft-versus-host disease. Br J Haematol 137:87– ogy Group study. Biol Blood Marrow Transplant 18:84–91, 2012.
98, 2007. 411. Stewart BL, Storer B, Storek J, et al: Duration of immunosuppressive treatment for
383. Mielcarek M, Storer BE, Boeckh M, et al: Initial therapy of acute graft-versus-host chronic graft-versus-host disease. Blood 104:3501–3506, 2004.
disease with low-dose prednisone does not compromise patient outcomes. Blood 412. Wolff D, Schleuning M, von Harsdorf S, et al: Consensus Conference on Clinical Prac-
113:2888–2894, 2009. tice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
384. Castilla-Llorente C, Martin PJ, McDonald GB, et al: Prognostic factors and outcomes of Biol Blood Marrow Transplant 17:1–17, 2011.
severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone 413. Abu-Dalle I, Reljic T, Nishihori T, et al: Extracorporeal photopheresis in steroid-
Marrow Transplant 49:966–971, 2014. refractory acute or chronic graft-versus-host disease: Results of a systematic review of
385. Couriel DR, Saliba R, de Lima M, et al: A phase III study of infliximab and corticos- prospective studies. Biol Blood Marrow Transplant 20:1677–1686, 2014.
teroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow 414. Koreth J, Matsuoka K, Kim HT, et al: Interleukin-2 and regulatory T cells in graft-
Transplant 15:1555–1562, 2009. versus-host disease. N Engl J Med 365:2055–2066, 2011.
386. Bolanos-Meade J, Logan BR, Alousi AM, et al: Phase III clinical trial steroids/mycophe- 415. Matsuoka K, Koreth J, Kim HT, et al: Low-dose interleukin-2 therapy restores regula-
nolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT tory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl
CTN 0802. Blood 124:3221–3227, 2014. Med 5:179ra43, 2013.
387. Martin PJ, Rizzo JD, Wingard JR, et al: First- and second-line systemic treatment of 416. Dubovsky JA, Flynn R, Du J, et al: Ibrutinib treatment ameliorates murine chronic
acute graft-versus-host disease: Recommendations of the American Society of Blood graft-versus-host disease. J Clin Invest 124:4867–4876, 2014.
and Marrow Transplantation. Biol Blood Marrow Transplant 18:1150–1163, 2012. 417. Mundt AJ, Sibley G, Williams S, et al: Patterns of failure following high-dose chemo-
388. Choi J, Cooper ML, Alahmari B, et al: Pharmacologic blockade of JAK1/JAK2 reduces therapy and autologous bone marrow transplantation with involved field radiotherapy
GvHD and preserves the graft-versus-leukemia effect. PLoS One 9:e109799, 2014. for relapsed/refractory Hodgkin’s disease. Int J Radiat Oncol Biol Phys 33:261–270,
389. Spoerl S, Mathew NR, Bscheider M, et al: Activity of therapeutic JAK 1/2 blockade in 1995.
graft-versus-host disease. Blood 123:3832–3842, 2014. 418. Holman PR, Costello C, deMagalhaes-Silverman M, et al: Idiotype immunization fol-
390. Fraser CJ, Bhatia S, Ness K, et al: Impact of chronic graft-versus-host disease on the lowing high-dose therapy and autologous stem cell transplantation for non-Hodgkin
health status of hematopoietic cell transplantation survivors: A report from the Bone lymphoma. Biol Blood Marrow Transplant 18:257–264, 2012.
Marrow Transplant Survivor Study. Blood 108:2867–2873, 2006. 419. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell
391. Pidala J, Kurland B, Chai X, et al: Patient-reported quality of life is associated with transplantation for multiple myeloma. N Engl J Med 366:1782–1791, 2012.
severity of chronic graft-versus-host disease as measured by NIH criteria: Report on 420. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplan-
baseline data from the Chronic GVHD Consortium. Blood 117:4651–4657, 2011. tation for multiple myeloma. N Engl J Med 366:1770–1781, 2012.
392. Baird K, Steinberg SM, Grkovic L, et al: National Institutes of Health chronic graft-ver- 421. Cohen S, Kiss T, Lachance S, et al: Tandem autologous-allogeneic nonmyeloablative
sus-host disease staging in severely affected patients: Organ and global scoring correlate sibling transplantation in relapsed follicular lymphoma leads to impressive progression-
with established indicators of disease severity and prognosis. Biol Blood Marrow Trans- free survival with minimal toxicity. Biol Blood Marrow Transplant 18:951–957, 2012.
plant 19:632–639, 2013. 422. Mielcarek M, Storer BE, Flowers ME, et al: Outcomes among patients with recurrent
393. Moon JH, Sohn SK, Lambie A, et al: Validation of National Institutes of Health global high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.
scoring system for chronic graft-versus-host disease (GVHD) according to overall and Biol Blood Marrow Transplant 13:1160–1168, 2007.
GVHD-specific survival. Biol Blood Marrow Transplant 20:556–563, 2014. 423. Duncan CN, Majhail NS, Brazauskas R, et al: Long-term survival and late effects among
394. Arora M, Klein JP, Weisdorf DJ, et al: Chronic GVHD risk score: A Center for Interna- 1-year survivors of second allogeneic hematopoietic cell transplantation for relapsed
tional Blood and Marrow Transplant Research analysis. Blood 117:6714–6720, 2011. acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 21:151–
395. Lee SJ, Klein JP, Barrett AJ, et al: Severity of chronic graft-versus-host disease: Associa- 158, 2015.
tion with treatment-related mortality and relapse. Blood 100:406–414, 2002. 424. Claret EJ, Alyea EP, Orsini E, et al: Characterization of T cell repertoire in patients
396. Carpenter PA: How I conduct a comprehensive chronic graft-versus-host disease with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 100:855–866,
assessment. Blood 118:2679–2687, 2011. 1997.
397. Carpenter PA: How to Conduct a Comprehensive Chronic GVHD Assessment. Vol. 2014. 425. Bachireddy P, Hainz U, Rooney M, et al: Reversal of in situ T-cell exhaustion dur-
Fred Hutchinson Cancer Research Center, Seattle, WA, 2011. ing effective human antileukemia responses to donor lymphocyte infusion. Blood
398. Chu YW, Gress RE: Murine models of chronic graft-versus-host disease: Insights and 123:1412–1421, 2014.
unresolved issues. Biol Blood Marrow Transplant 14:365–378, 2008. 426. Shanavas M, Messner HA, Kamel-Reid S, et al: A comparison of long-term outcomes
399. Srinivasan M, Flynn R, Price A, et al: Donor B-cell alloantibody deposition and germi- of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed
nal center formation are required for the development of murine chronic GVHD and CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma
bronchiolitis obliterans. Blood 119:1570–1580, 2012. Leuk 14:87–92, 2014.
400. Wagner JE, Thompson JS, Carter SL, et al: Effect of graft-versus-host disease prophy- 427. Collins RH Jr, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140
laxis on 3-year disease-free survival in recipients of unrelated donor bone marrow patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin
(T-cell Depletion Trial): A multi-centre, randomised phase II-III trial. Lancet 366:733– Oncol 15:433–444, 1997.
741, 2005. 428. Bar M, Sandmaier BM, Inamoto Y, et al: Donor lymphocyte infusion for relapsed hema-
401. Rotta M, Storer BE, Storb R, et al: Impact of recipient statin treatment on graft-ver- tological malignancies after allogeneic hematopoietic cell transplantation: Prognostic
sus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 19:949–957,
Transplant 16:1463–1466, 2010. 2013.
402. Arai S, Sahaf B, Narasimhan B, et al: Prophylactic rituximab after allogeneic trans- 429. Scarisbrick JJ, Dignan FL, Tulpule S, et al: A multicentre UK study of GVHD following
plantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood DLI: Rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow
119:6145–6154, 2012. Transplant 50:62–67, 2015.
403. Cutler C, Kim HT, Bindra B, et al: Rituximab prophylaxis prevents corticosteroid-re- 430. Keil F, Haas OA, Fritsch G, et al: Donor leukocyte infusion for leukemic relapse after
quiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts apla-
Results of a phase 2 trial. Blood 122:1510–1517, 2013. sia. Blood 89:3113–3117, 1997.
404. Wolff D, Gerbitz A, Ayuk F, et al: Consensus conference on clinical practice in chronic 431. Heimesaat MM, Nogai A, Bereswill S, et al: MyD88/TLR9 mediated immunopathology
graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host
Biol Blood Marrow Transplant 16:1611–1628, 2010. disease. Gut 59:1079–1087, 2010.

Kaushansky_chapter 23_p0353-0382.indd 381 9/19/15 12:47 AM